Immunitybio Inc IBRX

$8.31 -0.33 (-3.82%)

Valuation

Market cap
9,156,984,000
Revenue TTM
$113,290,000
Net income TTM
$-351,400,000
PE ratio
0.00
Forward PE
—
Profit margin
-310.18%
Debt to equity
0.00

Trading

Volume
12,731,801
Avg volume
12,225,092
Day's range
$8.02 – $8.84
Shares out
1,059,836,000
Stochastic %K
11%
Beta
0.02
Analysts
Strong Sell
Price target
$13.80

Price

Company profile

ImmunityBio, Inc., a biotechnology company, focuses on innovating, developing, and commercializing next-generation immunotherapies designed to activate the patient's immune system and deliver durable protection against cancer and infectious diseases. Its platforms for the development of biologic products and product candidates that include cytokine fusion proteins, DNA and vaccine vectors, and cell therapies. The com...

Show more

ImmunityBio, Inc., a biotechnology company, focuses on innovating, developing, and commercializing next-generation immunotherapies designed to activate the patient's immune system and deliver durable protection against cancer and infectious diseases. Its platforms for the development of biologic products and product candidates that include cytokine fusion proteins, DNA and vaccine vectors, and cell therapies. The company's platform has generated first-in-human therapeutic agents that are planned to be studied in clinical trials in liquid and solid tumors. Its lead biologic product candidate includes Anktiva, an FDA-approved immunotherapy in combination with bacillus calmette-guérin (BCG) for the treatment of adult patients with BCG unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors; and 3M-052, a synthetic TLR7/8 agonist and 3M-052 formulations and related technology. The company has collaboration agreements with National Cancer Institute; Serum Institute of India Private Limited; and BeOne Medicines Ltd. It has license agreement with 3M Innovative Properties Company and Access to Advanced Health Institute. ImmunityBio, Inc. is based in San Diego, California.

Industry
Biotechnology
Sector
Healthcare
Phone
844 696 5235
Website
https://immunitybio.com
Address
3530 John Hopkins Court, San Diego, United States

Latest news

Stocktwits

My_Lai_1968 Oct 23, 3:40 AM
$IBRX After a huge approval, this stock keeps falling? Why?
0 replies
Speedbaron Oct 23, 3:33 AM
$IBRX Vinay p and Adam f are my boys keep up the good work fellas.
1 replies
arnolddiver Oct 23, 3:06 AM
$IBRX FACT: Seeking Alpha is GARBAGE. Crazy as a lawyer, you’d post that crap. You dont find it odd Seeking Alpha posted this junk the day Papillary got approved. And why no mention of NAIVE?
0 replies
VolumeSpreadAnalysis Oct 23, 3:03 AM
$IBRX Price: $8.31 Volume: Above average Catalyst: Continued momentum from recent Ampligen/vaccine pipeline updates and biodefense contract speculation is fueling trader interest. Resistance: $9.10 Support: $7.60 Bull case: A clean break above $9.10 on strong volume could open the door toward $10+ as momentum buyers pile in. Bear case: Failure to hold $7.60 support risks a slide back toward $6.80 as profit-taking accelerates. What I'm watching: Watching for a volume-backed close above resistance or a breakdown below support to confirm the next directional move. Note: I’m not a financial advisor or a market predictor, and I don’t offer any premium subscriptions or paid services. Feel free to check out the link in my bio: @VolumeSpreadAnalysis
0 replies
survivor147 Oct 23, 2:59 AM
$IBRX Isn't it remarkable how many paid negative posters came out when the recent positive news was announced. But they never have anything but tired, fading arguments that are pitiful, weak, and irrelevant. If you are afraid, then you have no business here and should move on to calmer waters. Holding your shares for greater days ahead is going to prove beneficial to your long term financial health. Panic and you will be fleeced every time by the blackhearts
3 replies
Fitzhughlaw Oct 23, 2:45 AM
$IBRX Here's a good comparison of Anktiva vs. J&J's Inlexzo, including Inlexzo's infusion regimen. https://everyone.org/explore/compare? With J&J being a behemoth, it can devote a lot of money resources to an established sales and distribution network already in place. Note this excerpt from last week's Seeking Alpha article: "We can also consider the fact that at >$65K for a single implant, Inlexzo may be even more expensive than Anktiva, and ponder over study data that seems to make the case for Anktiva the most effective NMIBC treatment, while noting that Inlexzo was approved based on an 82% CR rate; however, with only 51% of patients maintaining their CR more than 12 months." I'm not sure how much this quarter's sales will mean to the institutions, because the jury is still out whether to embrace the bear case, i.e., just how much better Anktiva is when combined with BCG, as opposed to BCG alone.
2 replies
FindingFacts Oct 23, 2:24 AM
$IBRX Interesting, this is the reason why this stock will be a lot higher than this price. https://www.youtube.com/watch?v=7KFkZgWY5ZQ&pp=ugUEEgJlbg%3D%3D
1 replies
arnolddiver Oct 23, 2:10 AM
$IBRX BUT I do have a conspiracy theory. Dr Pat is finally playing ball! IMO many of us who have held thru 2025 thought it crazy Dr Pat was hitting the podcast circuit and talking crap about the FDA. Further alienating IBRX. Some even thought it was suicide. Some said it was the right move. Many thought the FDA’s decision for papillary would be slow walked to final bell Jan. But here we are 3 months early. Not only that but it comes b4 the NAIVE sbla. Think abt how important that is. The data lock is for Cohort A, CIS +/- Papillary. The papillary approval tells us the FDA is flexible to consider CIS and Papillary similar. This didnt take long to debate within the FDA. IMO there was added pressure coming from the Trump admin. Why would a republican politician buy stock for the first time? We’ve never seen it b4. So I hope that if Naive results are positive in Nov, this acts like a lit fuse for major fireworks. Dr Pat converting his debt to shares and bringing on some investing whales.
1 replies